Literature DB >> 17444427

Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.

David Widjaja1, Suresh Yarlagadda, Bheema S Singu, Raghu S Loganathan, Steve Blum, Alan Bloom, Prospere Remy.   

Abstract

BACKGROUND: In the United States, among patients with hepatocellular carcinoma (HCC) and portal hypertension from chronic hepatitis-B virus infection, 44% were Hispanic and 28% were African American. Because our institution (Bronx Lebanon Hospital Center, Bronx, NY) predominantly serves these populations, we studied retrospectively the characteristics of patients with chronic hepatitis-B virus infection.
METHODS: We reviewed the medical records of all patients aged > 18 years with chronic hepatitis-B virus infection who had been evaluated at our institution between January 1, 2002 and May 31, 2005.
RESULTS: We identified 167 patients with chronic hepatitis-B virus infection. Only 12 (7%) patients underwent chronic hepatitis-B virus treatment. One-hundred-forty-six (87%) patients without decompensated liver cirrhosis were not treated owing to the following reasons: normal alanine aminotransferase level (86%), active injection drug or heavy alcohol use (9%), lack of health insurance coverage (3%) and noncompliance with visits during the evaluation period (2%). HCC screening was performed in 78 patients (47%). Lack of insurance coverage and compliance issues were predictors for HCC screening (p = 0.04 and p < 0.001, respectively).
CONCLUSIONS: In the South Bronx, 87% patients were not considered candidates for hepatitis-B virus treatment because of normal alanine aminotransferase levels and the interference of potentially modifiable social factors. Only 47% of our patients with chronic hepatitis-B virus infection underwent HCC screening because of lack of insurance coverage and compliance issues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17444427      PMCID: PMC2569653     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  19 in total

1.  Chronic hepatitis B.

Authors:  A S Lok; B J McMahon
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

2.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

3.  Health insurance coverage for vulnerable populations: contrasting Asian Americans and Latinos in the United States.

Authors:  Margarita Alegría; Zhun Cao; Thomas G McGuire; Victoria D Ojeda; Bill Sribney; Meghan Woo; David Takeuchi
Journal:  Inquiry       Date:  2006       Impact factor: 1.730

4.  Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs.

Authors:  Susan T Goldstein; Miriam J Alter; Ian T Williams; Linda A Moyer; Franklyn N Judson; Karen Mottram; Michael Fleenor; Patricia L Ryder; Harold S Margolis
Journal:  J Infect Dis       Date:  2002-02-28       Impact factor: 5.226

Review 5.  Selecting appropriate management strategies for chronic hepatitis B: who to treat.

Authors:  Brian J McMahon
Journal:  Am J Gastroenterol       Date:  2006       Impact factor: 10.864

6.  Hepatitis B e antigen and the risk of hepatocellular carcinoma.

Authors:  Hwai-I Yang; Sheng-Nan Lu; Yun-Fan Liaw; San-Lin You; Chien-An Sun; Li-Yu Wang; Chuhsing K Hsiao; Pei-Jer Chen; Ding-Shinn Chen; Chien-Jen Chen
Journal:  N Engl J Med       Date:  2002-07-18       Impact factor: 91.245

7.  Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.

Authors:  G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

8.  The majority of hepatitis B carriers are not on regular surveillance in Singapore.

Authors:  C T Wai; B Mak; W Chua; S G Lim
Journal:  Singapore Med J       Date:  2004-09       Impact factor: 1.858

9.  Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys.

Authors:  P J Coleman; G M McQuillan; L A Moyer; S B Lambert; H S Margolis
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

10.  Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells.

Authors:  Jinah Choi; Ki Jeong Lee; Yanyan Zheng; Ardath K Yamaga; Michael M C Lai; Jing-Hsiung Ou
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

View more
  5 in total

Review 1.  Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States.

Authors:  Simona Ispas; Samuel So; Mehlika Toy
Journal:  J Community Health       Date:  2019-06

Review 2.  Chronic liver disease in the Hispanic population of the United States.

Authors:  Andres F Carrion; Ravi Ghanta; Olveen Carrasquillo; Paul Martin
Journal:  Clin Gastroenterol Hepatol       Date:  2011-05-12       Impact factor: 11.382

Review 3.  Hepatitis B and C in African Americans: current status and continued challenges.

Authors:  Kimberly A Forde; Orapin Tanapanpanit; K Rajender Reddy
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

4.  Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.

Authors:  Timothy Juday; Hong Tang; Melissa Harris; Annette Z Powers; Edward Kim; George J Hanna
Journal:  J Gen Intern Med       Date:  2010-10-27       Impact factor: 5.128

5.  Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.

Authors:  Mingjuan Tan; Ajeet S Bhadoria; Fuqiang Cui; Alex Tan; Judith Van Holten; Philippa Easterbrook; Nathan Ford; Qin Han; Ying Lu; Marc Bulterys; Yvan Hutin
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.